Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRATE II: Regorafenib-based regimens vs standard care in refractory advanced gastro-oesophageal cancer
jRCT2031250667Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of regorafenib and nivolumab in gastroesophageal junction adenocarcinoma (4 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoints: Overall survival (INTEGRATE IIa, overall population) and Overall survival (INTEGRATE IIb, overall population). Started Mar 2019; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250667.